Articles tagged "Sirolimus (SLR)"

2016 American Transplant Congress
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.
G. Basso, C. Felipe, A. Ferreira, M. Cristelli, N. Oliveira, T. Sandes-Freitas, J. Mansur, L. Viana, W. Aguiar, E. Campos, M. Gerbasi-DeLima, H. Tedesco-Silva, J. Medina-Pestana.
Hospital do Rim, São Paulo, Brazil.
The purpose of this analysis is to investigate the kinetics of cytomegalovirus (CMV) viral load in kidney transplant recipients receiving tacrolimus (TAC) plus everolimus (EVR)…
2016 American Transplant Congress
Effect of Conversion to mTOR Inhibition on Allograft Fibrosis in Pediatric Liver Transplantation.
R. Fischer,¹ S. Foster,² A. Kats,¹ W. Andrews,¹ R. Hendrickson,¹ J. Daniel.¹
¹Children's Mercy Hospital, Kansas City, MO; ²University of Kansas Medical Center, Kansas City, KS.
Background: Serial surveillance biopsies demonstrate post-transplant inflammation and fibrosis in long-surviving liver allografts. These findings can lead to cirrhosis and graft failure. We compared two…
2016 American Transplant Congress
Conversion from Tacrolimus (TAC) to Sirolimus (SLR)-Based Immunosuppression in Pediatric Patients Who Underwent Liver Transplantation for Unresectable Hepatoblastoma – 2 Year Follow-Up.
R. Hendrickson,¹ W. Andrews,¹ M. Davis,¹ R. Cisneros,¹ R. Fischer,² J. Daniel.²
¹Pediatric/Transplant Surgery, Children's Mercy Hospitals and Clinics, Kansas City, MO; ²Hepatology, Children's Mercy Hospitals and Clinics, Kansas City, MO.
Introduction: The appropriate use of Sirolimus (SRL) immunosuppression in pediatric liver transplantation has yet to be clearly defined. Even though Tacrolimus (TAC) is commonly used…
2016 American Transplant Congress
The Incidence of Symptomatic Pericardial Effusion with Long-Term Sirolimus Therapy.
N. Chandolias,¹ S. Wang,¹ A. Hahn,¹ R. Lyubarova,² R. Lopez-Soler,¹ D. Conti.¹
¹Surgery, Albany Medical College, Albany, NY; ²Cardiology, Albany Medical College, Albany, NY.
BACKGROUNDSirolimus is an approved agent for immunosuppressive therapy after renal transplantation. Pericardial effusion and tamponade have been recognized as potentially serious complications of long-term sirolimus…
2016 American Transplant Congress
Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients.
M. Burke,¹ L. Nahum,⁴ N. Isbel,¹ R. Carroll,³ H. Soyer,¹ R. Francis,¹ J. Bridge,¹ C. Staatz,² J. Wells.¹
¹Translational Research Institute, Brisbane, Australia; ²University of Queensland, Brisbane, Australia; ³Royal Adelaide Hospital, Adelaide, Australia; ⁴Ben Gurion University of the Negev, Beersheba, Israel.
BackgroundKidney transplant recipients (KTR) receiving sirolimus accrue fewer skin cancers than KTR receiving calcineurin inhibitor (CNI) based immunosuppression, potentially due to effects of sirolimus and…
2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
A. Santos, M. Casey, X. Wen, S. Rehman, K. Womer.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…
2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
S. Stead,¹ S. McInnes,² S. Kireta,³ P. Rose,¹ D. Rojas-Canales,³ S. Jesudason,³ S. Grey,⁴ R. Carroll,³ N. Voelcker,² P. Coates.^1,3
¹School of Medicine, University of Adelaide, Adelaide, Australia; ²Future Industries Institute, University of South Australia, Adelaide, Australia; ³CNARTS, Royal Adelaide Hospital, Adealide, Australia; ⁴Transplantation Immunology, Garvan Institute of Medical Research, Sydney, Australia.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…
2015 American Transplant Congress
Durability of Pancreatic Islets Transplantation in Brittle Type 1 Diabetics- 10 Year Follow Up
Z. Tekin,¹ L. Schenck,¹ M. Garfinkel,⁵ L. Philipson,² J. Thistlethwaite,¹ W. Chon,² K. Golab,¹ O. Savari,¹ S. Ramachandran,¹ K. Rezania,³ S. Hariprasad,⁴ J. Millis,¹ P. Witkowski.¹
¹Surgery, University of Chicago, Chicago, IL; ²Medicine, University of Chicago, Chicago, IL; ³Neurology, University of Chicago, Chicago, IL; ⁴Ophtalmology, University of Chicago, Chicago, IL; ⁵Surgery, Southern Illinois University, Springfield, IL.
The aim of the study was to assess long-term results of the pancreatic islet transplantation in our center.Methods: Human pancreatic islets were administered sequentially in…
2015 American Transplant Congress
Frequencies of CD4⁺25^hiFoxp3⁺T Cells in Long-Term Follow-Up of Sirolimus-Converted Kidney Transplant Recipients
O. Traitanon,^1,2 A. Alvarado,¹ E. Tantisattamo,^1,2 A. Shetty,^1,2 M. Ansari,^1,2 J. Mathew,¹ J. Leventhal,¹ V. Mas,³ L. Gallon.^1,2
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²Medicine-Nephrology, Northwestern University, Chicago, IL; ³Surgery, University of Virginia, Charlottesville, VA.
Background: Tacrolimus(TAC) and Sirolimus(SRL) are commonly used immunosuppressive drugs in kidney transplantation. SRL has been shown to induce the expansion of regulatory T cells in…
2015 American Transplant Congress
mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients
J. Fleming,¹ D. Taber,² N. Pilch,¹ H. Meadows,¹ C. Mardis,¹ J. McGillicuddy,² S. Nadig,² K. Chavin,² P. Baliga,² C. Bratton.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC.
The purpose of this study was to compare mTOR-based CNI withdrawal vs. minimization in African American (AA) kidney transplant (KTx) recipients.METHODS: This was a single-center,…